455 related articles for article (PubMed ID: 26990650)
1. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O
J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650
[TBL] [Abstract][Full Text] [Related]
2. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse.
Chou AH; Chen YL; Chiu CC; Yuan SJ; Weng YH; Yeh TH; Lin YL; Fang JM; Wang HL
Neuropharmacology; 2015 Dec; 99():308-17. PubMed ID: 26254860
[TBL] [Abstract][Full Text] [Related]
3. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
[TBL] [Abstract][Full Text] [Related]
4. Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice.
McLoughlin HS; Moore LR; Chopra R; Komlo R; McKenzie M; Blumenstein KG; Zhao H; Kordasiewicz HB; Shakkottai VG; Paulson HL
Ann Neurol; 2018 Jul; 84(1):64-77. PubMed ID: 29908063
[TBL] [Abstract][Full Text] [Related]
5. Polyglutamine-expanded ataxin-3 impairs long-term depression in Purkinje neurons of SCA3 transgenic mouse by inhibiting HAT and impairing histone acetylation.
Chou AH; Chen YL; Hu SH; Chang YM; Wang HL
Brain Res; 2014 Oct; 1583():220-9. PubMed ID: 25139423
[TBL] [Abstract][Full Text] [Related]
6. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
7. Vulnerability of frontal brain neurons for the toxicity of expanded ataxin-3.
Schmidt J; Mayer AK; Bakula D; Freude J; Weber JJ; Weiss A; Riess O; Schmidt T
Hum Mol Genet; 2019 May; 28(9):1463-1473. PubMed ID: 30576445
[TBL] [Abstract][Full Text] [Related]
8. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.
Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL
Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700
[TBL] [Abstract][Full Text] [Related]
9. Antisense Oligonucleotide Therapy Targeted Against ATXN3 Improves Potassium Channel-Mediated Purkinje Neuron Dysfunction in Spinocerebellar Ataxia Type 3.
Bushart DD; Zalon AJ; Zhang H; Morrison LM; Guan Y; Paulson HL; Shakkottai VG; McLoughlin HS
Cerebellum; 2021 Feb; 20(1):41-53. PubMed ID: 32789747
[TBL] [Abstract][Full Text] [Related]
10. Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3.
Boy J; Schmidt T; Wolburg H; Mack A; Nuber S; Böttcher M; Schmitt I; Holzmann C; Zimmermann F; Servadio A; Riess O
Hum Mol Genet; 2009 Nov; 18(22):4282-95. PubMed ID: 19666958
[TBL] [Abstract][Full Text] [Related]
11. Far-infrared Radiation Improves Motor Dysfunction and Neuropathology in Spinocerebellar Ataxia Type 3 Mice.
Liu SW; Chang JC; Chuang SF; Liu KH; Cheng WL; Chang HJ; Chang HS; Lin TT; Hsieh CL; Lin WY; Hsieh M; Kuo SJ; Liu CS
Cerebellum; 2019 Feb; 18(1):22-32. PubMed ID: 29725949
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model.
Toonen LJA; Overzier M; Evers MM; Leon LG; van der Zeeuw SAJ; Mei H; Kielbasa SM; Goeman JJ; Hettne KM; Magnusson OT; Poirel M; Seyer A; 't Hoen PAC; van Roon-Mom WMC
Mol Neurodegener; 2018 Jun; 13(1):31. PubMed ID: 29929540
[TBL] [Abstract][Full Text] [Related]
13. n-Butylidenephthalide exhibits protection against neurotoxicity through regulation of tryptophan 2, 3 dioxygenase in spinocerebellar ataxia type 3.
Rajamani K; Liu JW; Wu CH; Chiang IT; You DH; Lin SY; Hsieh DK; Lin SZ; Harn HJ; Chiou TW
Neuropharmacology; 2017 May; 117():434-446. PubMed ID: 28223212
[TBL] [Abstract][Full Text] [Related]
14. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.
Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Hirai H; Déglon N; de Almeida LP
PLoS One; 2013; 8(1):e52396. PubMed ID: 23349684
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological enhancement of retinoid-related orphan receptor α function mitigates spinocerebellar ataxia type 3 pathology.
Watanave M; Hoshino C; Konno A; Fukuzaki Y; Matsuzaki Y; Ishitani T; Hirai H
Neurobiol Dis; 2019 Jan; 121():263-273. PubMed ID: 30343032
[TBL] [Abstract][Full Text] [Related]
16. Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-Joseph disease.
Nascimento-Ferreira I; Nóbrega C; Vasconcelos-Ferreira A; Onofre I; Albuquerque D; Aveleira C; Hirai H; Déglon N; Pereira de Almeida L
Brain; 2013 Jul; 136(Pt 7):2173-88. PubMed ID: 23801739
[TBL] [Abstract][Full Text] [Related]
17. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.
Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC
Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone rescue cerebellar degeneration in SCA3 transgenic mice.
Wu S; Liu K; Cheng W; Su S; Lin Y; Lin T; Cheng Y; Chang J; Wu Y; Liu C
Biochem Biophys Res Commun; 2020 Aug; 529(2):467-473. PubMed ID: 32703453
[TBL] [Abstract][Full Text] [Related]
19. A Novel SCA3 Knock-in Mouse Model Mimics the Human SCA3 Disease Phenotype Including Neuropathological, Behavioral, and Transcriptional Abnormalities Especially in Oligodendrocytes.
Haas E; Incebacak RD; Hentrich T; Huridou C; Schmidt T; Casadei N; Maringer Y; Bahl C; Zimmermann F; Mills JD; Aronica E; Riess O; Schulze-Hentrich JM; Hübener-Schmid J
Mol Neurobiol; 2022 Jan; 59(1):495-522. PubMed ID: 34716557
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of NF-κB in astrocytes is sufficient to delay neurodegeneration induced by proteotoxicity in neurons.
Li YX; Sibon OCM; Dijkers PF
J Neuroinflammation; 2018 Sep; 15(1):261. PubMed ID: 30205834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
